Literature DB >> 11418883

Malaria chemoprophylaxis in the age of drug resistance. I. Currently recommended drug regimens.

K C Kain1, G D Shanks, J S Keystone.   

Abstract

As international travel becomes increasingly common and resistance to antimalarial drugs escalates, a growing number of travelers are at risk for contracting malaria. Parasite resistance to chloroquine and proguanil and real or perceived intolerance among patients to standard prophylactic agents such as mefloquine have highlighted the need for new antimalarial drugs. Promising new regimens include atovaquone and proguanil, in combination; primaquine; and a related 8-aminoquinoline, tafenoquine. These agents are active against the liver stage of the malaria parasite and therefore can be discontinued shortly after the traveler leaves an area where malaria is endemic, which encourages adherence to the treatment regimen. Part 1 of this series reviews currently recommended chemoprophylactic drug regimens, and part 2 will focus on 8-aminoquinoline drugs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11418883     DOI: 10.1086/321817

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  15 in total

Review 1.  Antiparasitic agent atovaquone.

Authors:  Aaron L Baggish; David R Hill
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

2.  Evaluation of the Makromed dipstick assay versus PCR for diagnosis of Plasmodium falciparum malaria in returned travelers.

Authors:  David C Richardson; Michele Ciach; Kathleen J Y Zhong; Ian Crandall; Kevin C Kain
Journal:  J Clin Microbiol       Date:  2002-12       Impact factor: 5.948

3.  Optimal Antimalarial Dose Regimens for Sulfadoxine-Pyrimethamine with or without Azithromycin in Pregnancy Based on Population Pharmacokinetic Modeling.

Authors:  Sam Salman; Francisca Baiwog; Madhu Page-Sharp; Susan Griffin; Harin A Karunajeewa; Ivo Mueller; Stephen J Rogerson; Peter M Siba; Kenneth F Ilett; Timothy M E Davis
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

4.  Inhibition of endosomal/lysosomal degradation increases the infectivity of human immunodeficiency virus.

Authors:  Brenda L Fredericksen; Bangdong L Wei; Jian Yao; Tianci Luo; J Victor Garcia
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

Review 5.  Malaria: progress, perils, and prospects for eradication.

Authors:  Brian M Greenwood; David A Fidock; Dennis E Kyle; Stefan H I Kappe; Pedro L Alonso; Frank H Collins; Patrick E Duffy
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

6.  Evaluation of anti-malarial effects of mass chemoprophylaxis in the Republic of Korea army.

Authors:  Joon-Sup Yeom; Seung-Ho Ryu; Sejoong Oh; Dong-Hyun Choi; Kyoung-Jun Song; Young-Ha Oh; Jae-Hyun Lee; Young-A Kim; Sun-Young Ahn; Hwa-Young Yang; Je-Eun Cha; Jae-Won Park
Journal:  J Korean Med Sci       Date:  2005-10       Impact factor: 2.153

7.  Pharmacokinetic properties of azithromycin in pregnancy.

Authors:  Sam Salman; Stephen J Rogerson; Kay Kose; Susan Griffin; Servina Gomorai; Francesca Baiwog; Josephine Winmai; Josin Kandai; Harin A Karunajeewa; Sean J O'Halloran; Peter Siba; Kenneth F Ilett; Ivo Mueller; Timothy M E Davis
Journal:  Antimicrob Agents Chemother       Date:  2009-10-26       Impact factor: 5.191

Review 8.  Atovaquone/proguanil: a review of its use for the prophylaxis of Plasmodium falciparum malaria.

Authors:  Kate McKeage; Lesley Scott
Journal:  Drugs       Date:  2003       Impact factor: 9.546

9.  Pyrimethamine and WR99210 exert opposing selection on dihydrofolate reductase from Plasmodium vivax.

Authors:  Michele D Hastings; Carol Hopkins Sibley
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-27       Impact factor: 11.205

10.  Epidemiology and clinical features of vivax malaria imported to Europe: sentinel surveillance data from TropNetEurop.

Authors:  N Mühlberger; T Jelinek; J Gascon; M Probst; T Zoller; M Schunk; J Beran; I Gjørup; R H Behrens; J Clerinx; A Björkman; P McWhinney; A Matteelli; R Lopez-Velez; Z Bisoffi; U Hellgren; S Puente; M L Schmid; B Myrvang; M L Holthoff-Stich; H Laferl; C Hatz; H Kollaritsch; A Kapaun; J Knobloch; J Iversen; A Kotlowski; D J M Malvy; P Kern; G Fry; H Siikamaki; M H Schulze; G Soula; M Paul; J Gómez i Prat; V Lehmann; O Bouchaud; S da Cunha; J Atouguia; G Boecken
Journal:  Malar J       Date:  2004-03-08       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.